Fewer than a tenth of patients that would benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its first advice on the drugs.
Considering more than one billion individuals worldwide now classified as obese, it is calling for increased and just access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidance acknowledges that obesity is a long-term condition that can be managed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to broad availability to the injections that can assist patients in reducing significant weight, explains the agency.
Skinny Jab Scarcity
Despite the current best projected outlook, the supply of these medications would only suffice for around 100 million people – under 10% of the global need, per the WHO.
The advice calls on governments and firms to increase availability, through measures like licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is set to lapse in a number of nations in 2026.
How Obesity Injections Operate
These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so users eat less.
Individuals commonly begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Evidence points to patients may see weight return within a year of discontinuing the medication, as their usual hunger resume.
To be above a healthy weight increases your likelihood for contracting diseases, like diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in every country and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
